The high expression of EGFR in brain cancers including glioma has led to its exploitation as a therapeutic target [33, 34], and we therefore evaluated the potential use of EGFR for targeting Dox-loaded minicells to brain tumor cells. This evidence concerns the gene EGFR and central nervous system cancer.